论文部分内容阅读
目的探讨索利那新联合坦索罗辛治疗前列腺增生(BPH)合并膀胱过度活动症(OAB)的临床疗效。方法选择前列腺增生患者95例,随机分成对照组和治疗组两组,对照组46例,口服坦索罗辛;治疗组49例,联合服用坦索罗辛和索利那新。两组分别在治疗前后以国际前列腺症状评分(IPSS)、膀胱过度活动症评分(OABSS)、储尿期评分、最大尿流率(Qmax)、残余尿量及24小时排尿次数、尿急次数、急迫性尿失禁次数和夜尿次数,观察其临床疗效。结果两组治疗前后IPSS、Qmax相比较,差异均有统计学意义(P<0.05),两组治疗后Qmax相比较,差异无统计学意义(P>0.05);对照组治疗前后OABSS、储尿期评分无统计学意义(P>0.05),治疗组治疗前后OABSS、储尿期评分差异有统计学意义(P<0.05);治疗组治疗后IPSS、OABSS、储尿期评分与对照组治疗后对比改善明显,差异有统计学意义(P<0.05);两组治疗前后及组间治疗后残余尿量对比均无明显差异(P>0.05),但均有一定的改善。两组治疗前后24h排尿次数、尿急次数、急迫性尿失禁次数、夜尿次数相比较,差异均有统计学意义(P<0.05),治疗组治疗后24h排尿次数、尿急次数、急迫性尿失禁次数、夜尿次数与对照组治疗后对比改善明显,差异有统计学意义(P<0.05)。两组均未发生尿潴留,不良事件发生率对照组为6.52%、治疗组为8.16%。结论索利那新联合坦索罗辛治疗BPH合并OAB较单用坦索罗辛疗效明显,不良反应轻微。
Objective To investigate the clinical efficacy of solifenacin combined with tamsulosin in the treatment of benign prostatic hyperplasia (BPH) and overactive bladder (OAB). Methods Ninety-five patients with benign prostatic hyperplasia (BPH) were randomly divided into control group and treatment group. 46 patients in control group received oral tamsulosin. In treatment group, 49 patients were treated with tamsulosin and solifenacin. Before and after treatment, the two groups were divided into three groups: IPSS, OABSS, QUR, Qmax, 24-hour urination, urinary urgency, The number of urinary incontinence and nocturia were observed and the clinical effect was observed. Results There were significant differences in IPSS and Qmax between the two groups before and after treatment (P <0.05). There was no significant difference in Qmax between the two groups after treatment (P> 0.05) (P> 0.05). There was significant difference in OABSS and urine storage before and after treatment in the treatment group (P <0.05). After treatment, the scores of IPSS, OABSS and urine storage in the treatment group were significantly lower than those in the control group (P <0.05). There was no significant difference in residual urine volume between the two groups before and after treatment and after treatment (P> 0.05), but both of them had some improvement. The urinary frequency, the number of urinary urgency, the number of urinary incontinence and the frequency of nocturia in both groups before and after treatment were significantly different (P <0.05). The number of urination, urinary urgency, urgency The number of urinary incontinence, nocturnal urination and control group improved significantly after treatment, the difference was statistically significant (P <0.05). No urinary retention occurred in either group. The incidence of adverse events was 6.52% in the control group and 8.16% in the treatment group. Conclusion Solifenac combined with tamsulosin in the treatment of BPH with OAB is more effective than tamsulosin alone with minimal adverse reactions.